Endocrine Abstracts

Background: Prader-Willi syndrome (PWS) is a rare genetic disorder evolving morbid obesity and growth hormone deficiency (GHD). Testing GH-IGF1 axis is required before treatment with rhGH in adults with PWS (1). The most common used tests in these patients are GHRH+arginine (GHRH+a) and insulin tolerance test. There are no prospective data for glucagon test (GT) in comparison to GHRH+a in adults with PWS. Mechanism by which GT causes GH release remains unclear, glucagon-induce...

Introduction: Prader Willi syndrome (PWS) is the most common syndromic form of obesity, caused by the absence of expression of the paternally active gens on the long arm of chromosome 15.The 16p11.2 microdeletion has recently been recognized as a syndromic condition appearing to be a predisposing factor for overweight, being the second most common genetic cause of obesity. One possible causative gen- SH2B1- involving leptin and insulin signaling, has been identified, although ...

Introduction: PWS is the most common cause of genetic obesity. These patients have an abnormal body composition with increased amounts of fat mass (FM), reduced lean body mass (LBM) and diminished bone mineral density (BMD), all similar to patients with growth hormone deficiency (GHD).The abnormal body composition has been described due to impairment of the activity of GH-IGF system and to hypogonadism. Studies ongrowth hormone (GH) treatment in PWS adults from other European ...

BackgroundCentral kisspeptin action is well known in reproductive regulation; however, its peripheral action is not well understood. Most studies reveal that kisspeptin signaling influences energy and metabolic status.ObjectiveTo compare serum kisspeptin levels 1) between adult patients with PWS, obese subjects matched for age, sex and BMI and healthy subjects; 2) in adult patients with PWS before and after t...